{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-24-000052","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.856301+00:00","generated_at":"2026-05-30T07:18:04.467767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam Q3 product revenue $420M (+34%); GAAP EPS -$0.87, guidance reaffirmed","bullets":["Global net product revenues $420M, up 34% YoY; TTR (ONPATTRO+AMVUTTRA) $309M, Rare (GIVLAARI+OXLUMO) $111M.","GAAP net loss $111.6M ($0.87 loss per share) vs. prior-year net income $147.8M ($1.18); Non-GAAP loss $64.2M ($0.50).","Submitted sNDA in U.S. and Type II Variation in EU for vutrisiran in ATTR-CM using Priority Review Voucher; potential U.S. launch early 2025.","Positive Phase 1 mivelsiran data in Alzheimer's: >90% sAPPβ lowering after second dose; no new safety signals. Ph2 planned year-end.","Suspended ALN-KHK development for type 2 diabetes; appointed Robert Hesslein as Chief Legal Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-24-000052","json":"https://secwatch.observer/filing/0001178670-24-000052.json","markdown":"https://secwatch.observer/filing/0001178670-24-000052.md","text":"https://secwatch.observer/filing/0001178670-24-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000052/0001178670-24-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000052/alny-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:18:04.467767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}